Summary by Moomoo AI
Medtronic reported Q1 fiscal 2025 revenue of $7.9 billion, up 3% year-over-year, with GAAP diluted EPS of $0.80 compared to $0.59 in the prior year. The growth was driven by strong performance across most businesses, particularly Diabetes (+12%), Neuromodulation (+9%), and Cardiac Rhythm & Heart Failure (+6%). Operating profit increased to $1.28 billion from $1.27 billion last year.The company saw broad-based growth across geographies, with U.S. revenue up 4% to $4.1 billion and international revenue up 1% to $3.8 billion. Performance was particularly strong in the Cardiovascular segment which grew 6% to $3.0 billion, while Neuroscience increased 4% to $2.3 billion. However, results were partially offset by a $90 million charge related to Italian payback accruals.Looking ahead, Medtronic remains focused on innovation and market expansion while managing various macro-economic challenges. The company maintained strong liquidity with $1.3 billion in cash and $6.5 billion in investments at quarter-end. During the quarter, Medtronic issued €3.0 billion in Senior Notes and repurchased 30 million shares at an average price of $82.28 per share.
